CAP

1836 Property Management Unveils Innovative Tool that Helps Real Estate Investors Monitor the Health and Success of Their Investment Properties - REI Monitor

Retrieved on: 
Wednesday, April 13, 2022
ROI, ROE, Property management, Appreciation, Review, Income, Multimedia, Partnership, CAP, Risk, REI, Goal, Tax, Commercial property, Security (finance)

AUSTIN, Texas, April 13, 2022 /PRNewswire/ -- 1836 Property Management, Austin's premier property management company, is helping clients reach their real estate investment goals by educating investors on best practices and ensuring properties are occupied and generating revenue.

Key Points: 
  • AUSTIN, Texas, April 13, 2022 /PRNewswire/ -- 1836 Property Management, Austin's premier property management company, is helping clients reach their real estate investment goals by educating investors on best practices and ensuring properties are occupied and generating revenue.
  • REI Monitor delivers the actual return-on-equity of an investment property in real-time.
  • The tool collects data such as monthly rental income, maintenance expenses, vacancy percentages, debt servicing costs (principal and interest payments made to the property), property equity, and other property expenses (i.e.
  • Investors can then monitor and establish benchmarks for normal ranges of ROI, vacancies, maintenance expenses and delinquent income.

DGAP-News: eDriving Announces International Collaboration with Bosch and Sfara

Retrieved on: 
Wednesday, April 13, 2022
Microsoft mobile services, Injury, Travel, CEO, Outsourcing, Carbon, Internet, CAP, SOS, Personal, Risk management, Running, Organization, World, Personal, Inc., Crash, Android, Solution, Smartphone, Technology, Insurance, ECall, Safety, UBI, Customer experience, Silicon, FICO, Business process, Risk, World Health Organization, Software as a service, IOS, GDPR, Mobile phone, Taxicab, Satellite navigation device, Solera

As a result of the collaboration, the Bosch emergency call service using the patented Sfara Automatic Crash Detection and Personal SOS technology will be integrated into eDriving's award-winning driver safety app, MentorSM .

Key Points: 
  • As a result of the collaboration, the Bosch emergency call service using the patented Sfara Automatic Crash Detection and Personal SOS technology will be integrated into eDriving's award-winning driver safety app, MentorSM .
  • With the integration of the patented Sfara technology, eCall and crash detection are now available in a smartphone-based solution.
  • "As a result of the collaboration between eDriving, Bosch and Sfara, organizations can protect their employees and contractors 24/7 from such circumstances should a crash occur while driving for work purposes," said Ed Dubens, CEO/Founder of eDriving.
  • Headquartered in Hoboken, NJ, Sfara also maintains operations in Silicon Valley, Finland and in Germany via Sfara GmbH.

Summit Health Opens New, State-of-the-Art Clinical Testing Laboratory

Retrieved on: 
Tuesday, April 12, 2022
Health, Hospitals, Other Health, General Health, Clinical Trials, Research, Science, Laboratory, CEO, STAT, Pain management, CAP, Microbiology, Quality control, College, Summit, Health, CLIA, Histology, Autoimmunity, CityMD, HPV, Patient, Multiple myeloma, Summit Medical Group, Allergy, Accreditation, Hospital, Central Oregon

One of the few physician group-owned laboratories in the country, the Summit Health lab enables timely and accurate diagnostic testing that informs providers medical decisions for patients.

Key Points: 
  • One of the few physician group-owned laboratories in the country, the Summit Health lab enables timely and accurate diagnostic testing that informs providers medical decisions for patients.
  • In addition to Summit Healths existing STAT laboratories located at its major hubs, which serve high acuity urgent care centers, the new Summit Health clinical lab, located at 1225 McBride Avenue in Woodland Park, NJ, will service all CityMD urgent care centers and Summit Health primary care and multispecialty offices for an expanded test offering.
  • The lab provides an expanded testing menu for Summit Health providers from routine tests to allergy, autoimmune, and urine drug toxicology for pain management.
  • Summit Health is a physician-driven, patient-centric network committed to simplifying the complexities of health care and bringing a more connected kind of care.

Indonesia Continues to Lead the Way in Site Blocking

Retrieved on: 
Monday, April 11, 2022
AVIA, YouGov, Association, General manager, Industry, CAP, Ecosystem, Consciousness, Cryptocurrency

The Indonesian government started blocking illegal sites in the middle of 2019 and by April this year the total number of sites blocked in Indonesia had topped 3,500.

Key Points: 
  • The Indonesian government started blocking illegal sites in the middle of 2019 and by April this year the total number of sites blocked in Indonesia had topped 3,500.
  • CAP's latest data also showed traffic to all pirate sites in Indonesia was down by 75% as of January this year compared to when tracking first started in September 2019.
  • Encouragingly traffic to legitimate sites in Indonesia had also tripled over the same period.
  • Local movie producer Edwin Nazir, the Chairman of Asosiasi Produser Film Indonesia (APROFI) was greatly encouraged by the ongoing blocking efforts and the positive traffic data.

OTT Summit Ends with Much Optimism for Growth in Asia and a Strong Focus on Content and the Consumer

Retrieved on: 
Wednesday, April 6, 2022
Business development, Paramount+, COO, AVIA, Parminder Singh Saini, Xandr, Average revenue per user, Endeavor Streaming, Growth, OTT, Association, Lumen Technologies, CJ, MPA, Aggregation, Discovery, Inc., Entrepreneurship, SVP, Chief digital officer, Mediacorp, Discovery, Associate Director of National Intelligence and Chief Information Officer, CJ ENM, Technology, Industry, Digital, CAP, Ecosystem, Nielsen, SVOD, Paramount, Pubmatic, Fatigue, Acquisition, Future, Mobile phone, Film, Video game, Asia-Pacific, TV5MONDE, Vindiciae contra tyrannos, Magnite

In discussing the outlook for the video industry in Asia, Vivek Couto, Executive Director and Co-Founder of Media Partners Asia (MPA), indicated there remained a lot of room for growth.

Key Points: 
  • In discussing the outlook for the video industry in Asia, Vivek Couto, Executive Director and Co-Founder of Media Partners Asia (MPA), indicated there remained a lot of room for growth.
  • However, while the region remained bullish on growth, the Average Revenue Per User remained low, particularly in the Philippines, Thailand, Indonesia, and India.
  • The adage of "Content is King" was very much heard throughout the summit.
  • The Asia Video Industry Association (AVIA) is the trade association for the video industry and ecosystem in Asia Pacific.

Inivata and Collaborators Publish New Data on RaDaR™ MRD Assay at AACR 2022

Retrieved on: 
Monday, April 11, 2022
Recurrence, Neoplasm, CLIA, Plasma, Principal, NASDAQ, MRD, DNA, Triangle Park (Quezon City), D, Netherlands Cancer Institute, NeoGenomics, University of Cambridge, Radar, AACR, Research, Biotechnology, American Association, Research Triangle Park, NSCLC, Laboratory, Cambridge Institute for Sustainability Leadership, MD, Squamous cell carcinoma, Association, American Association for Cancer Research, Technology, CAP, Cancer Research UK, Liquid biopsy, Cancer research, US, Nivolumab, University, Patient, Ipilimumab, Pharmaceutical industry, Medical imaging

Research Triangle Park, NC, USA and Cambridge, UK, 11 April 2022 -- Inivata, a leader in liquid biopsy, today unveils new data at the American Association for Cancer Research (AACR) Annual Meeting further demonstrating the potential of its RaDaR assay for the detection of minimal residual disease (MRD) and recurrence. The data being presented is from the NABUCCO study, which was run in collaboration with the Netherlands Cancer Institute.

Key Points: 
  • The data being presented is from the NABUCCO study, which was run in collaboration with the Netherlands Cancer Institute.
  • In the study, RaDaR was used to analyze circulating tumor DNA (ctDNA) to determine whether post-treatment ctDNA levels correlated with treatment response and outcome.
  • Along with continuing to generate clinical validation data, we will proceed with the regulatory pathway as we move towards commercialization of the assay.
  • RaDaR is Inivatas assay for the detection of minimal residual disease (MRD) and recurrence.

BIO-key International and 3Eye Technologies Partner to Deliver Identity-Bound Biometrics to New Markets

Retrieved on: 
Thursday, April 7, 2022
Identity management, As a service, Private Securities Litigation Reform Act, Company, VARS, Business development, Organization, NASDAQ, Computer security, Partnership, IAM, Marketing, The Act, Identity, Coronavirus, Risk, Program, Access management, Technology, History, U.S. Securities and Exchange Commission, Industry, CAP, International, COVID-19, IBB, GLOBE, Solution, VP, Member of the Scottish Parliament, Annual report, Insurance, Trust, Security (finance), Online shopping, Sales, Risk management, WALL

3Eye Technologies collaborates with vendors to plan and execute strategies for distributing cutting-edge technological solutions to targeted industries.

Key Points: 
  • 3Eye Technologies collaborates with vendors to plan and execute strategies for distributing cutting-edge technological solutions to targeted industries.
  • Trust in who has access to what is paramount to building trust both inside an organization and for customers.
  • By partnering with 3Eye Technologies, BIO-key will grow its Channel Alliance Partner (CAP) program, expand the use of IBB and continue to be a thought leader in the cybersecurity space.
  • BIO-key is the only IAM provider that offers Identity-Bound Biometrics, which are ideally suited for 3Eye Technologies' customers across multiple industries."

Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

Retrieved on: 
Monday, April 11, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Company, Drug development, Compugen (Israeli company), Biomarker, MIF, CLIA, DIA, Immunotherapy, NeoGenomics, Patient, GLP, AACR, Research, Proteome, Environment, American Association, Proteoform, Cancer, Norwich Pharma Services, Health, NEO, Marie Cassidy, Laboratory, Software, Association, CAP, GCP, Oncology, HRM, Nasdaq, Melanoma, Physician, Drug discovery, Solution, Information services, Data-independent acquisition, Protein, Proteomics, Partnership, Medical imaging, Pharmaceutical industry

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.

Key Points: 
  • Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.
  • The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.
  • At Biognosys, we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development, said Kristina Beeler, Ph.D., Chief Business Officer, Biognosys.
  • We are excited to now combine our proteomics platforms with NeoGenomics immuno-profiling platform to advance our biopharma partners oncology drug development programs.

The College of American Pathologists Welcomes New Director of Diversity, Equity and Inclusion

Retrieved on: 
Thursday, April 7, 2022
General Health, Other Health, Health, University, Education, Problem solving, Executive sponsor, ERG, Organization, University of Illinois Urbana-Champaign, College, Leadership, Mental health, Growth, District court, DEI, Patient, Research, Northern Illinois University, Pathology, Marie Cassidy, Organizational culture, Inclusion, CAP, Communication studies, The Honourable, State, Awareness, Law, Annual report, Education, Workplace, DE, United States district court, Orientation, Creativity, Management, Medicine, Equity, Northwestern University

joins the College of American Pathologists (CAP) as Director, Diversity, Equity and Inclusion.

Key Points: 
  • joins the College of American Pathologists (CAP) as Director, Diversity, Equity and Inclusion.
  • Diversity, Equity, and Inclusion means creating an organizational culture where all people, irrespective of their race, ethnicity, gender, orientation, abilities, etc., can thrive and realize their absolute fullest potential, said Dickinson-Creasey.
  • I am also laser focused on creating more awareness and education around diversity, equity, and inclusion within the workplace to better equip associates to be more intentional about inclusion.
  • She also served as the Executive Sponsor for ComPsychs Diversity, Equity, and Inclusion ERG fostering inclusion within the organization itself while supporting customers externally.

Artemis DNA, Genetic and Diagnostic Testing Company, Expands Services Internationally to Vietnam

Retrieved on: 
Monday, April 11, 2022
CLIA, World Health Organization, DNA, Neurology, Diagnosis, Decision-making, United Kingdom, Death, DNA sequencing, Reproductive health, Clinical Laboratory Improvement Amendments, Cardiology, ESG, Research, NGS, Woman, World, Topical steroid withdrawal, Cancer, Medicine, Man, Technology, CAP, Genetic testing, Lists of countries and territories, Genetics, Breast cancer, Patient, Partnership, Stomach, Vaccine, Medical imaging, Prostate, Artemis, DATAR

IRVINE, Calif., April 11, 2022 /PRNewswire/ -- Artemis DNA, Inc. ("Artemis DNA" or the "company"), a full-service, accredited, high complexity clinical diagnostic laboratory company providing proprietary Next Generation Sequencing (NGS) genetic and diagnostic testing that enables "personalized" medicine through early disease detection, proudly announced today that they will be opening their first international location at 253A Hoàng Sa, Phường Đa Kao, Quận 1 in Ho Chi Minh City, Vietnam.  Starting April 2022, Artemis DNA will begin offering its genetic testing technology and portfolio, as well as a new, revolutionary cancer screening called Trucheck™ Pragma through a partnership with Datar Cancer Genetics (Datar), a leading cancer research corporation specializing in non-invasive techniques for better diagnosis, treatment decisions, and management of cancer based in India and the United Kingdom.  The test, which was developed by Datar, uses blood samples and is intended for early detection of Prostate (men), Breast and Ovary (women), in addition to Lung, Stomach, and Colon/Pancreas cancers.

Key Points: 
  • Artemis DNA will begin offering groundbreaking cutting-edge genetic testing and early cancer detection technology to the people of Vietnam.
  • "TrucheckPragma is truly a remarkable advancement in cancer screening," commentedMs.Emylee Thai, Founder and Chairwoman of Artemis DNA.
  • The team at Artemis DNA is very excited to bring this cutting-edge technology for the people of Vietnam."
  • Artemis DNA also provides pre- and post-testing genetic education and counseling services, as well as conducting research and development to discover and develop additional novel diagnostic services.